Drugs / Trifluridine/Tipiracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06060704 | Nov 2023 → Mar 2025 | colorectal cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | “Drug: Trifluridine/Tipiracil” NCT06060704 ↗ |
| Route | Oral | “35 mg/m2 (maximum single dose of 80 mg), po” NCT06060704 ↗ |